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Sialyl Lewis x (sLex) is an established selectin ligand occurring on N- and O-linked glycans. Using a completely enzymic
approach starting from p-nitrophenyl N-acetyl-a-D-galactosaminide (GalNAc(a1-pNp as core substrate, the sLex-oligosac-
charide Neu5Ac(a2-3)Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp, representing the O-linked form, was syn-
thesized in an overall yield of 32%. In a first step, Gal(b1-3)GalNAc(a1-pNp was prepared in a yield of 52% using UDP-Gal
and an enriched preparation of b3-galactosyltransferase (EC 2.4.1.122) from rat liver. UDP-GlcNAc and a recombinant
affinity-purified preparation of core 2 b6-N-acetylglucosaminyltransferase (EC 2.4.1.102) fused to Protein A were used to
branch the core 1 structure, affording GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp in a yield of .85%. The core 2 structure was
galactosylated using UDP-Gal and purified human milk b4-galactosyltransferase 1 (EC 2.4.1.38) (yield of .85%), then
sialylated using CMP-Neu5Ac and purified recombinant a3-sialyltransferase 3 (EC 2.4.99.X) (yield of 87%), and finally
fucosylated using GDP-Fuc and recombinant human a3-fucosyltransferase 6 (EC 2.4.1.152) produced in Pichia pastoris
(yield of 100%). Overall 1.5 lmol of product was prepared. MALDI TOF mass spectra, and 1D and 2D TOCSY and ROESY 1H
NMR analysis confirmed the obtained structure.
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Abbreviations: b3-GalT, UDP-Gal:GalNAca-R b-1,3-galactosyltransferase, b3-galactosyltransferase; C2GnT, UDP-GlcNAc:
Gal(b1-3)GalNAc(a1-R (GlcNAc to GalNAc) b-1,6-N-acetylglucosaminyltransferase, b6-N-acetylglucosaminyltransferase; b4-
GalT1, UDP-Gal:GlcNAc b-1,4-galactosyltransferase 1, b4-galactosyltransferase 1; ST3Gal3, CMP-Neu5Ac:Gal(b1-4)GlcNAc
a-2,3-sialyltransferase 3, a3-sialyltransferase 3; a3-FucT6, GDP-Fuc:Gal(b1-4)GlcNAc (Fuc to GlcNAc) a-1,3-fucosyltrans-
ferase 6, a3-fucosyltransferase 6; Caco, sodium cacodylate (Na(CH3)2AsO2) - HCl buffer; CIAP, Calf Intestinal Alkaline
Phosphatase; core 1, Gal(b1-3)GalNAc; core 2, GlcNAc(b1-6)[Gal(b1-3)]GalNAc; core 4, GlcNAc(b1-6)[GlcNAc(b1-3)]GalNAc;
core 6, GlcNAc(b1-6)GalNAc; FPLC, Fast Protein Liquid Chromatography; HPLC, High Performance Liquid Chromatography;
LacNAc, Gal(b1-4)GlcNAc; lacto-N-biose, Gal(b1-3)GlcNAc; MALDI TOF, Matrix Assisted Laser Desorption Ionisation Time of
Flight; MES, 2-(N-Morpholino)ethanesulfonic acid - NaOH buffer; Me2SO, Dimethyl sulfoxide; MLEV, Malcolm Levitt; NMR,
Nuclear Magnetic Resonance; pNp, p-Nitrophenyl; PSGL-1, P-Selectin Glycoprotein Ligand 1; ROESY, Rotating Frame
Nuclear Overhauser Enhancement Spectroscopy; sLex, Sialyl Lewis x; TOCSY, Total Correlation Spectroscopy; WEFT, Water
Eliminated Fourier Transform.
Introduction
Selectin-mediated cell adhesion via the sialyl Lewis x (sLex)
epitope (Neu5Ac(a2-3)Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-)
[1,2] is playing an important role in many pathophysio-
logical processes, e.g. in cancer [3,4], inflammatory diseases
(reviewed in [5,6]),and acute rejections of solid organ trans-
plants [7]. Oligosaccharides containing the sLex structure
have been demonstrated in vivo [8] and in vitro [9] to inhibit
E-, L- and P-selectin-mediated adhesive interactions. Up till
now these components as well as their mimetics have been
tested and demonstrated to be beneficial in lung injury [10],
myocardial ischemia and reperfusion injury [11,12] as well
as in the inhibition of angiogenesis [13].
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Blocking sLex-selectin binding, therefore, represents a
highly relevant therapeutic target. To develop selectin
blockers, different strategies have been followed. Since the
first chemical synthesis of sLex in 1991 [14], several elegant
organic synthetic routes for this epitope have been de-
scribed [14–16]. Alternatively, enzymic as well as chemo-
enzymic approaches using glycosyltransferases and/or
glycosidases have been investigated [17,18]. The quite low
affinity of simple sLex oligosaccharides [19–21] as well as
the short life time in the circulation both led to the devel-
opment of multiple sLex-containing structures [22,23] and
numerous mimetics (reviewed in [24]), showing enhanced
binding properties compared to simple sLex [25,26]. While
the analogues may be toxic or antigenic, the synthesis of
complex glycoconjugates based on naturally occurring se-
lectin ligands seems to be a possible alternative. A promis-
ing candidate is the hexasaccharide O-linked to Thr57 of
the N-terminus of PSGL-1, one of the best characterized
glycoproteins involved in P- and E-selectin binding [27].
Here, we report the completely enzymic synthesis of O-
linked core 2 type sLex, Neu5Ac(a2-3)Gal(b1-4)[Fuc(a1-
3)] GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp, based on
the sequential transfer of appropriate monosaccharides
from nucleotide donors using suitable glycosyltransferases
as biocatalysts. The identify of this product is confirmed by
MALDI TOF mass spectrometry, 1D and 2D TOCSY and
ROESY 1H NMR analysis.
Materials and methods
Chemicals
All reagents were commercially available and of highest
purity unless otherwise noted. UDP-Gal, UDP-GlcNAc,
CMP-Neu5Ac, GDP-Fuc, and GalNAc(a1-pNp were pur-
chased from Sigma (Buchs, Switzerland). The correspond-
ing 14C-labeled nucleotide sugars were obtained from
Amersham International plc (Zürich, Switzerland). 2H2O
was purchased from Isotec (Veenendaal, The Netherlands),
HPLC-grade acetonitrile from Rathburn (Walkerburn,
Scotland), and ammonium bicarbonate and 6-aza-2-
thiothymine from Sigma (Zwijndrecht, The Netherlands).
Scintillant Irga-Safe Plus was purchased from Packard
(Zürich, Switzerland), and calf intestinal alkaline phos-
phatase (CIAP) from Boehringer Mannheim (Mannheim,
Germany).
Preparation of glycosyltransferases
b3-Galactosyltransferase (b3-GalT). Following the meth-
ods of Schachter and Brockhausen [28,29], 40 g of fresh rat
liver taken from 7 month old Long evans male were rinsed,
minced with scissors and homogenized in 80 ml of 50 mM
MES, pH 6.5, containing 250 mM sucrose and 20 mM
MgCl2, in a 1 l waring blendor (two 20 s burst at high
settings, with 40 s rest). After centrifugation at 680 g for 10
min, the pellet was homogenized using a Potter-Elvehjem
glass homogenizer with a motor driven pestle by making
three passes at 800 rpm. Then, the homogenate was centri-
fuged for 1 h at 10,000 g, and 22.5 ml of the pellet were
extracted five times overnight with intermediate centrifu-
gation at 100,000 g using equal volumes of 50 mM MES, pH
6.5, containing 5 mM MnCl2, 0.02% NaN3, 1% Triton X-
100, and 0.1 M NaCl. The highest activity was found in the
third extract after 3  days of incubation. All steps were
performed at 4 8C.
a3-Fucosyltransferase 6 (a3-FucT6). Human a3-FucT6
(GenBank Accession number M98825) was produced us-
ing the Pichia pastoris expression system from Invitrogen
(Groningen, The Netherlands). The generation of the
Pichia strain will be described elsewhere. Briefly, a strain
was used that secreted 1 U/l of a soluble form of a3-FucT6
into the supernatant, as measured by using N-acetyllac-
tosamine (LacNAc) as acceptor. The enzyme was enriched
by ultrafiltration and affinity-purified on GDP-hexano-
lamine-agarose.
Other glycosyltransferases. Recombinant mouse core 2
b6-N-acetylglucosaminyltransferase (C2GnT) (GenBank
Accession number U19265) was expressed as a Protein A
tagged soluble enzyme in CHO cells and purified as de-
scribed previously [30]. b4-Galactosyltransferase 1 (b4-
GalT1) was purified from human milk as described
previously [31]. Purified recombinant rat a3-sialyltrans-
ferase 3 (ST3Gal3) (GenBank Accession number M97754),
produced in Sf9 cells, was obtained as a gift from M. Streiff
(Novartis Pharma, Basel, Switzerland).
Enzymic synthesis protocols
The experimental conditions for the various steps in the
enzymic synthesis of Neu5Ac(a2-3) Gal(b1-4)[Fuc(a1-
3)]GlcNAc(b1-6) [Gal(b1-3)]GalNAc(a1-pNp are pre-
sented in Table 1. All incubations of saccharide acceptors
and nucleotide sugar donors in the presence of glycosyl-
transferases were carried out at 37 8C in a water bath,except
for the incubation related to b3-GalT (25 8C).
Yields were determined via parallel incubations with
14C-labeled nucleotide sugars, using 6-13% of the incuba-
tion mixtures; 20-ll samples of these mixtures were taken
at different time intervals. Reactions were stopped by add-
ing 0.5 ml of ice-cold water. Separations were carried out
on a Sep-Pak C18 cartridge (Waters, Milford, USA)
mounted on a vacuum chamber, equilibrated with 10 ml of
MeOH followed by 10 ml of H2O. To remove unreacted
radiolabeled nucleotide sugar, the cartridge was washed
with 15 ml of H2O. The non-radioactive acceptor and the
radiolabeled product were eluted with 5 ml of MeOH, and
the eluate was mixed with 10 ml of scintillant Irga-Safe
Plus. Typically, cpm values of 1,000–5,000 were counted.
The non-radioactive incubation mixtures were separated
as mentioned above, using three sequentially coupled Sep-
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Pak C18 cartridges. In each case, the MeOH phase was con-
centrated in a Speed vac,and the residues were used directly
in the next glycosylation step, except prior to the fucosyla-
tion.
After the sialylation and fucosylation steps, the products
were purified via gel filtration and HPLC. Reaction mix-
tures were desalted on Sephadex G-25 (FPLC system;
HiTrap, 4 3 5 ml bedvolume; Pharmacia, Uppsala, Sweden)
using 5 mM ammonium hydrogen carbonate as eluent at a
flow rate of 1.5 ml/min, and subsequent lyophilization. Ef-
fluents were monitored by UV at 214 nm, and conductivity.
Sephadex G-25 fractions were further purified by HPLC
on a ChromSpher 5 C8 reversed phase column (10 3 250
mm, Chrompack, Bergen op Zoom, The Netherlands) at a
flow rate of 2.0 ml/min using a Kratos SF 400 HPLC system
(ABI Analytical, Kratos Division). The column was eluted
isocratically with solvent  A (aqueous 80% acetonitrile)
during 5 min, followed by a gradient from 100% solvent A
- 0% solvent B (aqueous 20% acetonitrile) to 65% solvent
A - 35% solvent B in 18 min. The effluents were monitored
at 280 nm using a 757 absorbance detector (ABI Analytical,
Kratos Division). The collected fractions were immediately
lyophilized for further analysis.
Mass Spectrometry
Negative-ion mode MALDI TOF mass spectrometric
analysis of the products was performed on a Voyager-DE
(PerSeptive Biosystems) instrument operating at an accel-
erating voltage of 22 kV (grid voltage 92%, ion guide wire
voltage 0.1%) and equipped with a VSL-337ND-N2 laser.
The samples were dissolved in bidistilled water (1 lg/ll)
and subsequently mixed in the sample well with 6-aza-2-
thiothymine (10 mg/ml in water:acetonitrile 1:1, v/v) at a
ratio of 1:3. Linear mass scans were recorded over 1000
Dalton using a pulse delay time of 90 ns. Recorded data
were processed using GRAMS/386 software (v. 3.04, Galac-
tic Industries Corporation).
NMR Spectroscopy
Prior to analysis the reaction products  were repeatedly
exchanged in 2H2O (99.9 atom % 2H) with intermediate
Table 1. Reaction parameters used for the sequential build-up of the core 2 type sLex epitope
Temperature Time Step
Step Acceptor Donor Transferase (8C) Other Components (h) yield
1a 15 mM (510.3 mg) 20 mM (524.4 mg) enriched rat liver 25 1% Triton X-100 72 29%*
GalNAc(a1-pNp UDP-Gal b3-GalT (5.6 mU) 10% Me2SO
0.1 M MES pH 6.5
10 mM MnCl2
60 U CIAP
1b 10 mM (510.3 mg) 20 mM (524.4 mg) enriched rat liver 25 1% Triton X-100 72 23%*
GalNAc(a1-pNp UDP-Gal b3-GalT (3 mU) 10% Me2SO 52%
0.1 M MES pH 6.5 total
10 mM MnCl2
60 U CIAP
2 20 mM (57.8 mg) 25 mM (512.6 mg) recombinant mouse 37 0.1 M MES pH 6.5 32 85%*
Gal(b1-3)GalNAc(a1-pNp UDP-GlcNAc C2GnT (64 mU) 10 mM MgCl2
3 10 mM (58.7mg) 15 mM (511.3 mg) human milk 37 0.1 M Tris-HCl pH 7.4 5 85%*
GlcNAc(b1-6)[Gal UDP-Gal b4-GalT1 (200 mU) 10 mM MgCl2
(b1-3)]GalNAc(a1-pNp
4a 10 mM (58.3 mg) 15 mM (58.8 mg) recombinant human 37 0.1 M Caco pH 6.8 16 27%*
Gal(b1-4)GlcNAc(b1-6)[Gal CMP-Neu5Ac ST3Gal3 (170 mU) 10 mM MgCl2
(b1-3)]GalNAc(a1-pNp 2 mM CaCl2
20 U CIAP
4b 10 mM (57.7 mg) 15 mM (58 mg) recombinant human 37 0.1 M Caco pH 6.8 5 60%*
Gal(b1-4)GlcNAc(b1-6)[Gal CMP-Neu5Ac ST3Gal3 (72 mU) 10 mM MgCl2 87%
(b1-3)]GalNAc(a1-pNp 2 mM CaCl2 total*1
20 U CIAP
5 3.5 mM (52 mg) 20 mM (56 mg) recombinant human 37 25 mM Caco pH 6.2 6 100%*1
Neu5Ac(a2-3)Gal(b1-4) GDP-Fuc a3-FucT6 (70 mU) 5 mM ATP
GlcNAc(b1-6)[Gal 10 mM Fuc
(b1-3)]GalNAc(a1-pNp 10 mM MnCl2
20 U CIAP
*Calculated by radioactive labeled parallel incubations. Yields are given on the basis of acceptor used for the specific reaction. 1Calculated from the
HPLC profile.
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lyophilization and finally dissolved in 450 ll 2H2O (99.96
atom % 2H). Resolution-enhanced 1H 1D and 2D NMR
spectra were recorded on Bruker AMX-500, DRX-500 or
DRX-600 (Department of NMR Spectroscopy, Utrecht
University) spectrometers, at probe temperatures of 300 K.
Chemical  shifts (d) were expressed in parts per million
relative to internal acetate (d 1.908; acetone d 2.225).
HO2H signal suppression was achieved by applying a
WEFT pulse sequence [32] in 1D 1H experiments and by
presaturation for 1 s in 2D experiments. 2D TOCSY spectra
were recorded by using MLEV-17 mixing sequences [33]
with effective spin-lock times between 20 and 100 ms. 2D
ROESY [34] spectra were recorded with a mixing time of
250 ms. The spin-lock field strength corresponded to a 908
pulse of about 120 ls. A 2D 600 MHz off-resonance
ROESY spectrum of the final product was recorded ac-
cording to [35]. The spin-lock field strength corresponded
to a 908 pulse of about 115 ls. 1H 1D and 2D spectra were
processed on Silicon Graphics IRIS work stations (Indigo
2 and O2) using XINSP2 software (Bijvoet Center, Depart-
ment of Bio-Organic Chemistry).
Results
Enzymic synthesis of the mucin-type sialyl Lewis x
epitope
A survey of the strategy and the amounts of donors, ac-
ceptors, and glycosyltransferases used to build up the O-
linked hexasaccharide, Neu5Ac(a2-3)Gal(b1-4)[Fuc(a1-3)]
GlcNAc(b1-6) [Gal(b1-3)]GalNAc(a1-pNp, bearing the
sLex epitope, are presented in Table 1. Yields were deter-
mined via parallel incubations with radioactive nucleotide
sugar donors (see Materials and methods). During prelimi-
nary studies, the individual glycosyltransfer reactions (ex-
cept for the sialylation) were optimized, and the products
Gal(b1-3)GalNAc(a1-pNp(1), Gal(b1-4)GlcNAc(b1-6)
[Gal(b1-3)]GalNAc(a1-pNp (2), and Gal(b1-4)[Fuc(a1-3)]
GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp (3) were puri-
fied for characterization by mass spectrometry and 1H
NMR spectroscopy (Table 2). Therefore, in the complete
enzymic synthesis, as described below, the steps 1–4 were
carried out without intermediate chromatographic purifica-
tions and detailed structural analysis.
GalNAc(a1-pNp was chosen as a starting core substrate.
This compound was elongated to yield Gal(b1-3)Gal-
NAc(a1-pNp by using UDP-Gal and a rat liver b3-GalT
(EC 2.4.1.122; 0.5 U/g) Triton X-100 extract. To increase the
yield, calf intestinal alkaline phosphatase (EC 3.1.3.1; 2500
U/mg) was added [36]. Even though the activity at 25 8C
was only 67% compared to an incubation at 37 8C, 25 8C
was chosen because of a better stability of the transferase.
Furthermore, it was found that at least 17% of UDP-Gal
was degraded at 25 8C within 24 h. For this reason, after 3
days of incubation (step 1a) fresh UDP-Gal and enzyme
preparation were added for another 3 days of incubation
(step 1b). In step 1a the product yield was 29%; via step 1b
an overall yield of 52% was reached.
For the branching of the core 1 structure Gal(b1-3)Gal-
NAc(a1-pNp, yielding the core 2 structure, UDP-GlcNAc
and purified mouse recombinant C2GnT (EC 2.4.1.102)
were applied (step 2). Mouse C2GnT was expressed as a
Protein A fusion in CHO cells [30]. GlcNAc(b1-6)[Gal(b1-
3)]GalNAc(a1-pNp was obtained in a yield of 85% after 32
h of incubation.
The core  2 structure  was further elongated at O4 of
GlcNAc using UDP-Gal and purified human milk b4-
GalT1 (step 3). Under the applied conditions Gal(b1-4)
GlcNAc(b1-6) [Gal(b1-3)]GalNAc(a1-pNp was generated
in a yield of .85% after 5 h of incubation.
To sialylate the tetrasaccharide, CMP-Neu5Ac and puri-
fied recombinant rat ST3Gal3 (EC 2.4.99.X) were used [37].
In two sequential incubations of 16 h and 5 h (step 4; for
conditions, see Table 1) Neu5Ac(a2-3)Gal(b1-4)GlcNAc
(b1-6)[Gal(b1-3)]GalNAc(a1-pNp (4) was synthesized in a
total yield of 87%. For the purification use was made of
HiTrap chromatography and reversed phase HPLC.
Finally, the pentasaccharide (4) was fucosylated with
GDP-Fuc in the presence of recombinant enriched human
a3-FucT6 (EC 2.4.1.152) (step 5), affording the sLex epi-
tope-containing title compound 5 after 6 h of incubation in
a yield of 100%, as observed by HPLC and supported by a
radioactive parallel incubation. In contrast to insect cell
supernatant [38] no exoglycosidase degrading the acceptor
substrate for a3-FucT6 could be detected.
Taken together, 1.5 lmol of the mucin-type sLex-con-
taining hexasaccharide could  be  prepared in  an overall
yield of 32%, whereby the individual yield of each step is
calculated on the basis of the acceptor used.
Structural analysis of synthesized products 4 and 5
The negative-ion mode MALDI TOF mass spectrum (Fig-
ure 1a) of compound 4 showed one intense signal at m/z
1159.4, corresponding to the deprotonated pseudo-molecu-
lar ion of a pentasaccharide with the brutoformula Neu5
AcHex2HexNAc2-pNp (calculated mass 1159.4)
The 1D 1H NMR spectrum (Figure 2a) of compound 4
revealed three main resonances downfield of the HO2H
signal (d 4.766) at d 8.307 (3Jm,o 9.0 Hz), 7.269 (3Jo,m 9.0 Hz)
and 5.805 (3J1,2 4.0 Hz)(Table 2). The two most downfield
signals were assigned to the m- and o-protons of the p-ni-
trophenyl aglycon [39], respectively, while the remaining
resonance was attributed to the anomeric proton of Gal-
NAc (A; pyranose ring form), a-glycosidically linked to the
p-nitrophenyl aglycon. Upfield of the HO2H resonance
three additional anomeric resonances at d 4.538 (3J1,2 7.5
Hz), 4.467 (3J1,2 7.5 Hz) and 4.447 (3J1,2 7.5 Hz) were iden-
tified and assigned to b-1,3-linked Gal3 (B; pyranose ring
form), b-1,6-linked GlcNAc (C; pyranose ring form), and
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Table 2. 500 and 600-MHz 1H-NMR chemical shifts of pNp-oligosaccharides recorded at 300K referenced to internal acetate d 1.908
(acetone d 2.225). Compounds are represented by symbolic shorthand notation: , GalNAc; d, GlcNAc; j2, Gal4; j⁄, Gal3; u, Fuc;
and n, Neu5Ac.
1 2 3 4 5
Reporter
Residue group
pNp C6H49 8.272(9.0) 8.306(9.0) 8.304(9.0) 8.307(9.0) 8.310(9.0)
C6H4 7.281(9.0) 7.270(9.0) 7.265(9.0) 7.269(9.0) 7.270(9.0)
GalNAc H-1 5.831(4.0) 5.810(4.0) 5.805(4.0) 5.805(4.0) 5.807(4.0)
H-2 4.580 4.568 4.565 4.564 4.566
H-3 4.293 4.294 4.293 4.291 4.291
H-4 4.316 4.305 4.304 4.303 4.303
H-5 4.023 4.182 4.167 4.187 4.187
H-6a 3.738 3.771 3.730 3.776 3.763
H-6b 3.762 3.999 3.998 3.989 3.994
CH3 2.013 2.004 2.002 2.003 2.006
GlcNAc H-1 - 4.472(7.5) 4.485(7.5) 4.467(7.5) 4.482(7.5)
H-2 - 3.593 3.765 3.583 3.764
H-3 - 3.498 3.765 3.487 3.764
H-4 - 3.664 3.761 3.663 3.745
H-5 - 3.503 3.512 3.588 3.512
H-6a - 3.595 3.701 n.d. 3.563
H-6b - 3.904 3.917 3.971 n.d.
CH3 - 1.901 1.886 1.899 1.890
Gal4 H-1 - 4.386(7.5) 4.370(7.5) 4.447(7.5) 4.428(7.5)
H-2 - 3.512 3.468 3.540 3.504
H-3 - 3.650 3.629 4.097 4.096
H-4 - 3.918 3.889 3.951 3.935
H-5 - n.d. 3.697 n.d. 3.717
Gal3 H-1 4.548(7.5) 5.541(7.5) 4.539(7.5) 4.538(7.5) 4.545(7.5)
H-2 3.560 3.555 3.549 3.553 3.555
H-3 3.657 3.654 3.639 3.654 3.646
H-4 3.932 3.933 3.927 3.928 3.937
H-5 n.d. n.d. 3.652 n.d. 3.704
H-6a n.d. n.d. 3.857 n.d. 3.881
H-6b n.d. n.d. 3.765 n.d. 3.740
Fuc H-1 - - 5.034(4.0) - 5.030(4.0)
H-2 - - 3.651 - 3.645
H-3 - - 3.771 - 3.763
H-4 - - 3.849 - 3.849
H-5 - - 4.776 - 4.777
CH3 - - 1.151(6.5) - 1.147(6.5)
Neu5Ac H-3a - - - 1.790 1.789
H-3e - - - 2.753 2.763
H-4 - - - 3.670 3.667
H-5 - - - 3.834 3.848
H-6 - - - 3.636 3.636
H-7 - - - n.d. 3.605
H-8 - - - n.d. 3.889
H-9a - - - n.d. 3.865
H-9b - - - n.d. 3.649
CH3 - - - 2.030 2.036
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b-1,4-linked Gal4 (D;  pyranose ring form),  respectively
(compare with compounds 1–3 in Table 2 and literature
data [39]). The three N-acetyl resonances representing
three protons each, at d 2.030, 2.003 and 1.899 could be
attributed to Neu5Ac, GalNAc and GlcNAc, respectively
[39]. The presence of only one Neu5Ac residue (E) in this
oligosaccharide was confirmed by comparing the intensi-
ties of the H3e and H3a resonances at d 2.753 and 1.790,
respectively, with those of the discrete signals of the p-ni-
trophenyl moiety.
By means of 2D TOCSY most of the resonances present
in the 1D spectrum could be identified (Table 2, compound
4). In the TOCSY spectrum (100 ms, not shown) the
anomeric track of the Gal4 residue D revealed three cross-
peaks at d 3.540 (H2), 4.097 (H3), and 3.951 (H4). When
compared to the corresponding signals of precursor 2, these
resonances showed downfield shifts of 0.028 ppm for Gal4
H2, 0.447 ppm for Gal4 H3, and 0.033 ppm for Gal4 H4,
indicating that Neu5Ac is linked at O3 of Gal4. The
anomeric track of the Gal3 residue B revealed three cross-
peaks at d 3.553 (H2), 3.654 (H3), and 3.928 (H4), in agree-
ment with the terminal position of this residue (c.f.
compound 2, Table 2), thereby excluding a possible sialyla-
tion of the Gal3 residue. The ST3Gal3-side activity on core 1
galactose as observed by Kono et al. [40] was absent in our
case. The combined MS and NMR results justify the conclu-
sion that oligosaccharide 4 has the structure Neu5Ac (a2-3)
Gal(b1-4)GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp.
The  negative-ion mode MALDI  TOF mass spectrum
(Figure 1b) of compound 5 showed one major peak at m/z
1305.0 corresponding to the deprotonated pseudo-molecu-
lar ion of a hexasaccharide with the brutoformula Neu5Ac
Hex2dHexHexNAc2-pNp (calculated mass 1305.4).
The 1D 1H NMR spectrum (Figure 2b) of compound 5
revealed five anomeric signals at d 5.807 (3J1,2 4.0 Hz), 5.030
(3J1,2 4.0 Hz), 4.545 (3J1,2 7.5 Hz), 4.482 (3J1,2 7.5 Hz), and
Figure 1. MALDI TOF mass spectra (negative-ion mode) of (a) Neu5AcHex2HexNAc2-pNp, and (b) Neu5AcHex2dHexHexNAc2-pNp.
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4.428 (3J1,2 7.5 Hz), which could be identified on guidance
of the NMR data of compounds 1–4 (Table 2). The addi-
tional anomeric resonance at d 5.030 in compound 5 be-
longed to the incorporated a-Fuc residue (G;pyranose ring
form). 2D TOCSY NMR spectroscopy allowed the identi-
fication of most of the signals (Table 2). The introduction of
Fuc at O3 of GlcNAc (C) in 4 resulted in distinct downfield
shifts of GlcNAc H1 (0.015 ppm), H2 (0.181 ppm), H3
(0.277 ppm), and H4 (0.082 ppm), a feature which is also
observed when the NMR data of compounds 2 and 3 are
compared (Table 2).
In order to confirm the various glycosidic linkages in
compound 5 a 2D off-resonance ROESY (Figure 3) experi-
ment was performed. The interresidual cross-peaks be-
tween Gal3 H1 and Ga1NAc H3 (d 4.545/4.291), GlcNAc
H1 and GalNAc H6a (d 4.482/3.763), Fuc H1 and GlcNAc
Figure 2. One-dimensional 500 MHz or 600 MHz 1H NMR spectra of (a) Neu5Ac(a2-3)Gal(b1-4) GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp (4) (500
MHz) and (b) Neu5Ac(a2-3)Gal(b1-4) [Fuc(a1-3)]GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp (5) (600 MHz) in 2H2O at 300 K (referenced to internal
acetone (d 2.225)). Assignment in the Figure: A 5 GalNAc, B 5 Gal3, C 5 GlcNAc6, D 5 Gal4,6, E 5 Neu5Ac, F 5 Fuc.
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Figure 3. Two-dimensional 600 MHz ROESY spectrum (mixing time 200 ms) of Neu5Ac(a2-3)Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-6)[Gal(b1-3)]Gal-
NAc(a1-pNp (5) in 2H2O at 300 K (referenced to internal acetone (d 2.225)).
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H3 (d 5.030/3.764), and between Gal4 H1 and GlcNAc H4
(d 4.428/3.745) proved the presence of the Gal(b1-3)
GalNAc, GlcNAc(b1-6)GalNAc, Fuc(a1-3)GlcNAc, and
Gal(b1-4)GlcNAc linkages, respectively. It should be noted
that the interresidual cross-peak between Neu5Ac H3e and
Gal4 H3 as reported by Ball et al. [41] was not observed in
our study. The combined MS and NMR data indicate that
oligosaccharide 5 has the structure Neu5Ac(a2-3)Gal(b1-
4)[Fuc(a1-3)]GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp.
Discussion
The production of selectin blockers seems to be a reward-
ing task with respect to several therapeutic targets, such as
inflammatory diseases, transplant rejection and metastasis.
This new class of anti-adhesion compounds can be enzymi-
cally generated by taking advantage of the high stereo- and
regioselectivity of glycosyltransferases. This approach
which ascertains an easy access to the naturally occurring
PSGL-1 type sLex epitope, in relatively high yields, opens
the possibility for the synthesis of glycopeptides by making
use of the four cloned animal polypeptide GalNAc-trans-
ferases [42–46]. The  structural identity  with the natural
ligand would not only render these compounds highly com-
patible in the competition with PSGL-1, but also assure a
prolonged life-time and reduced antigenicity when com-
pared with the non-natural ligands.
To demonstrate the suitability of glycosyltransferases for
the synthesis of complex oligosaccharides, we used Gal-
NAc(a1-pNp as the starting substrate for the elongation of
O-linked glycans. As shown previously [30] the branching
C2GnT has a strict requirement for a 3-substitution of Gal-
NAc. Even though a b3-GalT, involved in the GM1/GD1
synthesis, transferring Gal to lipid-linked GalNAc [47], has
been cloned, yet no recombinant enzyme is available elon-
gating peptide-bound GalNAc. The rapid degradation of
UDP-Gal in our system correlates well with the observation
[48] that UDP-Gal decomposes rapidly in the presence of
Mn21, a metal ion needed to maintain b3-GalT activity.
Therefore,a two step incubation was carried out,resulting in
a final yield of 52% for Gal(b1-3)GalNAc(a1-pNp (core 1
structure).
To date three different C2GnTs, of use for the branching
of the core 1 structure, have been cloned [49–51]. Two of
the three transferases [50,51] are also capable of synthesiz-
ing the core 4 structure (GlcNAc(b1-6)[GlcNAc(b1-3)]
GalNAc). As shown recently, the core 1 disaccharide can
alternatively be branched with the b-N-acetyl-D-hexos-
aminidase from Nocardia orientalis [52]; unfortunately, the
yield is only around 6%. Applying a crude mouse kidney
C2GnT preparation, the branching of a core 1 structure
was realized in a yield of 74% [53]. By the use of a recom-
binant purified mouse C2GnT we achieved a yield of
.85% for GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp
(core 2 structure).
Recently,b-galactosidase from bovine testes was used in a
one pot reaction together with a recombinant b-1,6-GlcNAc
transferase. The galactosidase, which reversibly links galac-
tose via a (b1-3) linkage to N-acetylgalactosamine, provides
the substrate for the GlcNAc transferase in situ [54]. Since
this synthesis ended up with a mixture of core 2 and core 6
(GlcNAc(b1-6)GalNAc) structures, and can only be driven
towards high yields of the core 6 structure (yield .90%), we
preferred the use of a crude b3-GalT preparation in combi-
nation with C2GnT.
The core 2 structure can be galactosylated at O4 of
GlcNAc by various b4-GalTs. By now, a whole family of
b4-GalTs has been identified and cloned (reviewed in [55]).
Although b4-GalT1 has been reported to be inefficient for
the elongation of the core 2 structure [56], the purified hu-
man milk enzyme, known as b4-GalT1, was successfully ap-
plied to extend the core 2 structure, yielding Gal(b1-4)
GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp. In spite of the
earlier reported data that a strong inhibition of b4-GalT1
should exist for core 2 acceptor concentrations of 5 mM [53],
we were able to reach a yield of .85% with 200 mU of
enzyme at an acceptor concentration of 10 mM. It should be
noted that within 5 h of incubation we did not achieve the
earlier reported 100% yield with the enzyme used in [53].
The tetrasaccharide as generated above, was further ex-
tended by sialic acid using ST3Gal3. Out of the four to date
cloned  enzymes only ST3Gal3  and ST3Gal4  have been
demonstrated to sialylate N-acetyllactosamine (LacNAc)
[40]. In our studies we used purified recombinant rat
ST3Gal3, despite the preference of this enzyme for Gal
(b1-3)GlcNAc (lacto-N-biose). Both ST3Gal3 and
ST3Gal4 have a side activity in sialylating the Gal residue
in a core 1 structure [40]. However,  Gal(b1-4)GlcNAc
(b1-6)[Neu5Ac(a2-3)Gal(b1-3)] GalNAc(a1-pNp was not
found in our incubation mixture. This indicates that the side
activity is strictly confined to the absence of a Gal(b1-4)X
and the presence of a Gal(b1-3)X acceptor. Using a similar
substrate in an earlier study, a yield of 68% was obtained
with the partially purified recombinant rat ST3Gal3 [53].
Here, we obtained Neu5Ac(a2-3)Gal(b1-4)GlcNAc(b1-
6)[Gal(b1-3)]GalNAc(a1-pNp in a yield of 87% via a two
step incubation using 170 and 72 mU of the purified en-
zyme.
To obtain the sLex epitope, the foregoing structure was
fucosylated at O3 of GlcNAc. At present five cloned a3-
FucTs (a3-FucT3 - a3-FucT7), displaying different acceptor
specificities, are known. a3-FucT4 fucosylates nearly ex-
clusively LacNAc, whereas a3-FucT7 only acts on (a2-3)-
sialylated LacNAc [57,58]. a3-FucT6, used in this study,
fucosylates both sialylated and non-sialylated LacNAc.This
enzyme, which has been shown to be highly active in vivo
[59], is also of interest for the preparation of difucosyl sLex
structures on poly-LacNAc chains [60]. The expression sys-
tem for a3-FucT6,used in our study,prevails over the system
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described by Licari et al. [38], since no exoglycosidases are
present in the supernatant which cause degradation of the
acceptor substrate. In a 6 h incubation with 70 mU of re-
combinant a3-FucT6, Neu5Ac(a2-3)Gal(b1-4)[Fuc(a1-3)]
GlcNAc(b1-6)[Gal(b1-3)]GalNAc(a1-pNp was synthe-
sized in 100% yield.
In summary, we performed the first full enzymic synthe-
sis of a core 2 type sLex-containing hexasaccharide in an
overall yield of about 32%. Once recombinant b3-GalT
forming the core 1 structure will become available, scaling-
up of the procedure described here should be feasible.
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